Loading organizations...
Massachusetts Avenue Capital (MAC) operates as an early-stage venture capital firm, dedicating its resources to investments across the deep technology, biotechnology, and distributed/decentralized technology sectors. The firm specializes in identifying and nurturing innovative startups that possess the potential for significant disruption and advancement within these complex, high-growth domains, leveraging a focused technical approach to its portfolio selection.
Established in 2016, Massachusetts Avenue Capital was formed with the strategic insight to provide crucial early-stage funding and support to emerging companies in specialized technology areas. While the firm maintains a lean public profile regarding its founding members, it commenced operations within the vibrant Boston innovation ecosystem, aligning itself with a rich pool of technical talent and research institutions.
MAC primarily collaborates with startups located within the greater Boston area, serving as a strategic partner to facilitate their scaling and market entry. The firm's overarching vision is to actively contribute to the development of foundational technologies by supporting pioneering companies, thereby aiming to cultivate substantial advancements and generate enduring value across its core investment industries.
Mass Ave Capital has 1 tracked investment across 1 company. The latest tracked deal is $25.0M Seed in Hopewell Therapeutics in June 2023.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jun 7, 2023 | Hopewell Therapeutics | $25.0M Seed | — | 5Y Capital, BOPU Capital, IMO Ventures, WS Investments |